VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer

Stopped early · Phase 2

Conditions studied: Lung Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy for the treatment of patients who have recurrent small cell lung cancer following treatment.

Key facts

Study ID

NCT00003847

Run by

Vertex Pharmaceuticals Incorporated

People needed

36

Starts

1998-12-01

Last updated by the study team

2013-09-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States
• Indiana University Cancer Center — Indianapolis, Indiana, United States
• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Fallon Clinic Inc. — Worcester, Massachusetts, United States
• St. John's Mercy Medical Center — St Louis, Missouri, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• Duke Comprehensive Cancer Center — Durham, North Carolina, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.